These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34304374)

  • 1. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
    Monahan C; McCoy L; Powell J; Gums JG
    Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
    Gao J; Li J; Lu X; Yang J
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination.
    Price MZ; Price RL
    Prim Care Companion CNS Disord; 2024 Apr; 26(2):. PubMed ID: 38579267
    [No Abstract]   [Full Text] [Related]  

  • 12. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.
    Salem H; Samir E; Mazen DZ; Madian H; Elkhateeb AE; Elaraby M; Rasekh MI; Gamal A
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121105. PubMed ID: 35272122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
    Chambers A; Patton J; Wills BK
    Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Much of an Advance Is the Addition of Samidorphan to Olanzapine?
    Buchanan RW
    Am J Psychiatry; 2020 Dec; 177(12):1113-1114. PubMed ID: 33256454
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
    Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
    CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.